Back to CVE records
High 7.1HealthcarePublished Mar 11, 2026

CVE-2026-32126OpenEMR: Inverted ACL Condition in CDR ControllerRouter Allows Any Authenticated User to Modify/Delete Clinical Rules and Plans

Updated under an hour ago ()

Does this affect you?

It affects openemr and 1 other product. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 0.50%, higher than 41% of scored CVEs.

OpenEMR is a free and open source electronic health records and medical practice management application. Prior to 8.0.0.1, an inverted boolean condition in ControllerRouter::route() causes the admin/super ACL check to be enforced only for controllers that already have their own internal authorization (review, log), while leaving all other CDR controllers — alerts, ajax, edit, add, detail, browse — accessible to any authenticated user. This allows any logged-in user to suppress clinical decision support alerts system-wide, delete or modify clinical plans, and edit rule configurations — all operations intended to require administrator privileges. This vulnerability is fixed in 8.0.0.1.

CVSS
7.1 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:L
Weakness (CWE)
CWE-862
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
0.50% (percentile 41)
Assigned by
GitHub_M
NVD analysis
Analyzed
Record last updated
Mar 12, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
openemr openemr
openemr:openemr (from the name)
before 8.0.0.1
CNA record
open-emr openemr
open-emr:openemr
before 8.0.0.1
NVD

References

  • x-refsource-confirm, exploit, vendor-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.